Which hedge funds own TRAW? TRAWS PHARMA INC, Q2 2026 13F holders
10 of the hedge funds tracked by WhaleCreep disclosed a position in TRAW (TRAWS PHARMA INC) in their Q2 2026 13F filings, worth $4.3m in total. The largest holder by portfolio weight is Ally Bridge Group (ny) LLC at 0.9% of its book. 4 managers opened a new position this quarter: Ally Bridge Group (ny) LLC, Sphera Funds Management Ltd., Kynam Capital Management, LP, Alyeska Investment Group, L.P.. 2 exited: Squadron Capital Management LLC, Two Sigma Investments, LP.
10tracked managers holding
4opened this quarter
2exited this quarter
Which hedge funds hold TRAW? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Ally Bridge Group (ny) LLC | Q2 2026 | 0.9% | $663.0k | 786,236 | – | new |
| Ikarian Capital, LLC | Q2 2026 | 0.1% | $403.2k | 478,142 | -29% | reduced |
| Lynx1 Capital Management LP | Q2 2026 | 0.1% | $471.8k | 559,470 | 3611% | added |
| Sphera Funds Management Ltd. | Q2 2026 | 0.0% | $336.0k | 398,486 | – | new |
| Adar1 Capital Management, LLC | Q2 2026 | 0.0% | $504.1k | 597,729 | 288% | added |
| Orbimed Advisors LLC | Q2 2026 | 0.0% | $1.0m | 1,203,260 | 99% | added |
| Kynam Capital Management, LP | Q2 2026 | 0.0% | $71.2k | 84,400 | – | new |
| Boothbay Fund Management, LLC | Q2 2026 | 0.0% | $112.9k | 133,936 | -31% | reduced |
| Adage Capital Partners GP, L.L.C. | Q2 2026 | 0.0% | $615.6k | 730,000 | 0% | held |
| Alyeska Investment Group, L.P. | Q2 2026 | 0.0% | $138.6k | 164,376 | – | new |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Squadron Capital Management LLC | 1.4% | $936.4k |
| Two Sigma Investments, LP | 0.0% | $35.2k |
How has hedge fund ownership of TRAW changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 10 | $4.3m |
| Q1 2026 | 8 | $5.3m |
| Q4 2024 | 1 | $89.3k |
| Q2 2024 | 1 | $97.4k |
| Q1 2024 | 1 | $271.0k |
| Q4 2023 | 1 | $148.0k |
| Q3 2023 | 1 | $131.0k |
| Q2 2023 | 1 | $277.0k |
| Q1 2023 | 1 | $106.0k |
| Q4 2022 | 1 | $108.0k |
| Q3 2022 | 1 | $181.0k |
| Q2 2022 | 1 | $440.0k |
| Q1 2022 | 1 | $592.0k |
| Q4 2021 | 1 | $341.0k |
Counts every tracked manager that disclosed TRAW in that quarter's filing, including managers that have since stopped filing.